Cardiovascular risks of androgen deprivation therapy for prostate cancer

被引：1
|
作者：
Miller, K. [1 ]
机构：
[1] Klin & Hsch Ambulanz Urol, Charitepl 1, D-10117 Berlin, Germany
来源：
UROLOGE | 2016年 / 55卷 / 05期
关键词：
Prostate cancer; Androgen deprivation therapy; Cardio vascular events; GnRH antagonists; LHRH agonists; MEN; DISEASE; ASSOCIATION; SUPPRESSION; MORBIDITY; MORTALITY;
D O I：
10.1007/s00120-015-0021-1
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer. It has increasingly been used in other stages of the disease as well. Besides well-known side effects caused by the lack of testosterone (impotency, osteoporosis, fatigue, loss of muscle mass), an increase of cardiovascular (CV) morbidity and mortality has recently been discussed in association with ADT. Cardiovascular side effects cannot be sufficiently explained by low testosterone levels. This review gives an overview of the recent literature, interprets the results, and offers clinical consequences.
引用
收藏
页码：627 / 631
页数：5
相关论文
共 50 条
  • [31] PROSTATE CANCER Cardiovascular mortality and androgen deprivation
    Basaria, Shehzad
    NATURE REVIEWS UROLOGY, 2009, 6 (05) : 252 - 253
  • [32] Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
    Isbarn, Hendrik
    Boccon-Gibod, Laurent
    Carroll, Peter R.
    Montorsi, Francesco
    Schulman, Claude
    Smith, Matthew R.
    Sternberg, Cora N.
    Studer, Urs E.
    EUROPEAN UROLOGY, 2009, 55 (01) : 62 - 75
  • [33] Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
    Teoh, Jeremy Yuen Chun
    Ng, Chi-Fai
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (09) : 1429 - 1435
  • [34] Does androgen deprivation therapy in men with prostate cancer increase cardiovascular morbidity?
    Steven M Corsello
    Philip W Kantoff
    Nature Clinical Practice Urology, 2008, 5 : 80 - 81
  • [35] Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
    Jeremy Yuen Chun Teoh
    Chi-Fai Ng
    International Urology and Nephrology, 2016, 48 : 1429 - 1435
  • [36] Questioning the reality of an increase in cardiovascular mortality with androgen deprivation therapy for prostate cancer?
    Buvat, J.
    BASIC AND CLINICAL ANDROLOGY, 2011, 21 : 227 - 229
  • [37] Re: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
    Mongiat-Artus, Pierre
    EUROPEAN UROLOGY, 2008, 53 (06) : 1297 - 1297
  • [38] Supervised exercise to reduce cardiovascular morbidity of androgen deprivation therapy for prostate cancer
    Wong, William W.
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (01): : 5 - 7
  • [39] Risk of Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer Comment
    Kunath, Frank
    Wullich, Bernd
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (02) : 144 - 145
  • [40] Cardiovascular Disease Risk and Androgen Deprivation Therapy in Patients with Localized Prostate Cancer
    Haque, Reina
    Xu, Xiaoqing
    Yood, Marianne Ulcickas
    Cassidy-Bushrow, Andrea E.
    Van den Eeden, Stephen K.
    Potosky, Arnold L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 323 - 324
12345